New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - glucose monohydrate 55 g/l;   - solution for infusion - 5 % - active: glucose monohydrate 55 g/l   excipient: hydrochloric acid sodium hydroxide water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanine 14 g/l;  ;  ; arginine 12 g/l;  ;  ; calcium chloride dihydrate 0.56 g/l (as dihydrate. equivalent to 0.74 g/l calcium chloride dihydrate);  ; glycine 11 g/l;  ;  ;  ; histidine 3 g/l;  ;  ;  ; isoleucine 5 g/l;  ;  ;  ; leucine 7.4 g/l;  ;  ;  ;  ; lysine acetate 9.3 g/l equivalent to l-lysine 6.6 g/l;  ;  ; magnesium sulfate 1.2 g/l (as heptahydrate. equivalent to 2.47 g/l magnesium sulphate heptahydrate);  ;  ; methionine 4.3 g/l;  ;  ; phenylalanine 5.1 g/l;  ;  ; potassium chloride 4.48 g/l;  ; proline 11.2 g/l;  ; serine 6.5 g/l;  ;  ;  ; sodium acetate trihydrate 3.4 g/l (as trihydrate. equivalent to sodium acetate trihydrate 5.62 g/l);  ;  ;  ; sodium glycerophosphate 4.18 g/l (as hydrate. amount added corrected for actual water content of substance);  ; taurine 1 g/l;  ; threonine 4.4 g/l;  ;  ;  ; tryptophan 2 g/l;  ;  ;  ; tyrosine 0.4 g/l;  ; valine 6.2 g/l;  ;  ;  ;  ; zinc sulfate 0.023 g/l (as heptahydrate. equivalent to zinc sulphate 0.0129 g);  ; glucose monohydrate 462 g/l equivalent to glucose (anhydrous) 420 g/l;  ;  ; fish oil 30 g/l; medium-chain triglycerides 60 g/l;  ; olive oil 50 g/l;  ; soya oil 60 g/l;   - emulsion for infusion - active: alanine 14 g/l     arginine 12 g/l     calcium chloride dihydrate 0.56 g/l (as dihydrate. equivalent to 0.74 g/l calcium chloride dihydrate)   glycine 11 g/l       histidine 3 g/l       isoleucine 5 g/l       leucine 7.4 g/l         lysine acetate 9.3 g/l equivalent to l-lysine 6.6 g/l     magnesium sulfate 1.2 g/l (as heptahydrate. equivalent to 2.47 g/l magnesium sulphate heptahydrate)     methionine 4.3 g/l     phenylalanine 5.1 g/l     potassium chloride 4.48 g/l   proline 11.2 g/l   serine 6.5 g/l       sodium acetate trihydrate 3.4 g/l (as trihydrate. equivalent to sodium acetate trihydrate 5.62 g/l)       sodium glycerophosphate 4.18 g/l (as hydrate. amount added corrected for actual water content of substance)   taurine 1 g/l   threonine 4.4 g/l       tryptophan 2 g/l       tyrosine 0.4 g/l   valine 6.2 g/l         zinc sulfate 0.023 g/l (as heptahydrate. equivalent to zinc sulphate 0.0129 g)   excipient: glacial acetic acid nitrogen water for injection active: glucose monohydrate 462 g/l equivalent to glucose (anhydrous) 420 g/l     excipient: hydrochloric acid nitrogen water for injection active: fish oil 30 g/l medium-chain triglycerides 60 g/l   olive oil 50 g/l   soya oil 60 g/l   excipient: dl-alpha tocopherol egg lecithin glycerol nitrogen sodium hydroxide sodium oleate water for injection - parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - glucose monohydrate 12.1% equivalent to 11% glucose anhydrous;  ;  ;  ; alanine 1.6%;  ;  ;  ; arginine 1.13%;  ;  ;  ;  ; aspartic acid 0.34%;  ;  ;  ;  ;  ; calcium chloride dihydrate 0.074%;  ; glutamic acid 0.56%;  ;  ;  ;  ;  ; glycine 0.79%;  ;  ;  ;  ;  ; histidine 0.68%;  ;  ;  ;  ; isoleucine 0.56%;  ;  ;  ;  ;  ; leucine 0.79%;  ;  ;  ;  ;  ; lysine hydrochloride 0.9%;  ;  ;  ;  ;  ;  ; magnesium sulfate heptahydrate 0.16%;  ;  ; methionine 0.56%;  ;  ;  ;  ;  ; phenylalanine 0.79%;  ;  ;  ;  ;  ;  ; potassium chloride 0.597%;  ; proline 0.68%;  ; serine 0.45%;  ;  ;  ;  ;  ; sodium acetate trihydrate 0.49%;  ;  ; sodium glycerophosphate 0.54%;  ;  ; threonine 0.56%;  ;  ;  ; tryptophan 0.19%;  ;  ;  ; tyrosine 0.023%;  ;  ;  ; valine 0.73%;  ;  ;  ;  ; soya oil 20% - emulsion for injection - active: glucose monohydrate 12.1% equivalent to 11% glucose anhydrous       excipient: water for injection active: alanine 1.6%       arginine 1.13%         aspartic acid 0.34%           calcium chloride dihydrate 0.074%   glutamic acid 0.56%           glycine 0.79%           histidine 0.68%         isoleucine 0.56%           leucine 0.79%           lysine hydrochloride 0.9%             magnesium sulfate heptahydrate 0.16%     methionine 0.56%           phenylalanine 0.79%             potassium chloride 0.597%   proline 0.68%   serine 0.45%           sodium acetate trihydrate 0.49%     sodium glycerophosphate 0.54%     threonine 0.56%       tryptophan 0.19%       tyrosine 0.023%       valine 0.73%         excipient: glacial acetic acid water for injection active: soya oil 20% excipient: egg lecithin glycerol sodium hydroxide water for injection - parenteral nutrition for adult patients and children above 2 years of age when oral or enteral nutrition is impossible or insufficient or contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - glucose monohydrate 20.9% equivalent to 19% glucose anhydrous;  ;  ;  ; alanine 1.6%;  ;  ;  ; arginine 1.13%;  ;  ;  ;  ; aspartic acid 0.34%;  ;  ;  ;  ;  ; calcium chloride dihydrate 0.074%;  ; glutamic acid 0.56%;  ;  ;  ;  ;  ; glycine 0.79%;  ;  ;  ;  ;  ; histidine 0.68%;  ;  ;  ;  ; isoleucine 0.56%;  ;  ;  ;  ;  ; leucine 0.79%;  ;  ;  ;  ;  ; lysine hydrochloride 0.9%;  ;  ;  ;  ;  ;  ; magnesium sulfate heptahydrate 0.16%;  ;  ; methionine 0.56%;  ;  ;  ;  ;  ; phenylalanine 0.79%;  ;  ;  ;  ;  ; potassium chloride 0.597%;  ; proline 0.68%;  ; serine 0.45%;  ;  ;  ;  ; sodium acetate trihydrate 0.49%;  ;  ; sodium glycerophosphate 0.54%;  ;  ;  ; threonine 0.56%;  ;  ;  ; tryptophan 0.19%;  ;  ;  ; tyrosine 0.023%;  ;  ;  ; valine 0.73%;  ;  ;  ;  ; soya oil 20% - emulsion for injection - active: glucose monohydrate 20.9% equivalent to 19% glucose anhydrous       excipient: water for injection active: alanine 1.6%       arginine 1.13%         aspartic acid 0.34%           calcium chloride dihydrate 0.074%   glutamic acid 0.56%           glycine 0.79%           histidine 0.68%         isoleucine 0.56%           leucine 0.79%           lysine hydrochloride 0.9%             magnesium sulfate heptahydrate 0.16%     methionine 0.56%           phenylalanine 0.79%           potassium chloride 0.597%   proline 0.68%   serine 0.45%         sodium acetate trihydrate 0.49%     sodium glycerophosphate 0.54%       threonine 0.56%       tryptophan 0.19%       tyrosine 0.023%       valine 0.73%         excipient: glacial acetic acid water for injection active: soya oil 20% excipient: egg lecithin glycerol sodium hydroxide water for injection - parenteral nutrition for adult patients and children above 2 years of age when oral or enteral nutrition is impossible or insufficient or contraindicated.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanine 14 g/l;  ;  ; arginine 12 g/l;  ;  ; glycine 11 g/l;  ;  ;  ; histidine 3 g/l;  ;  ;  ; isoleucine 5 g/l;  ;  ;  ; leucine 7.4 g/l;  ;  ;  ;  ; lysine acetate 9.3 g/l equivalent to l-lysine 6.6 g;  ;  ; methionine 4.3 g/l;  ;  ; phenylalanine 5.1 g/l;  ;  ; proline 11.2 g/l;  ; serine 6.5 g/l;  ;  ;  ; taurine 1 g/l;  ; threonine 4.4 g/l;  ;  ;  ; tryptophan 2 g/l;  ;  ; tyrosine 0.4 g/l;  ; valine 6.2 g/l;  ;  ;  ;  ; glucose monohydrate 462 g/l equivalent to glucose (anhydrous) 420 g/l;  ;  ; fish oil 30 g/l; medium-chain triglycerides 60 g/l;  ; olive oil 50 g/l;  ; soya oil 60 g/l;   - emulsion for infusion - active: alanine 14 g/l     arginine 12 g/l     glycine 11 g/l       histidine 3 g/l       isoleucine 5 g/l       leucine 7.4 g/l         lysine acetate 9.3 g/l equivalent to l-lysine 6.6 g     methionine 4.3 g/l     phenylalanine 5.1 g/l     proline 11.2 g/l   serine 6.5 g/l       taurine 1 g/l   threonine 4.4 g/l       tryptophan 2 g/l     tyrosine 0.4 g/l   valine 6.2 g/l         excipient: glacial acetic acid nitrogen water for injection active: glucose monohydrate 462 g/l equivalent to glucose (anhydrous) 420 g/l     excipient: hydrochloric acid nitrogen water for injection active: fish oil 30 g/l medium-chain triglycerides 60 g/l   olive oil 50 g/l   soya oil 60 g/l   excipient: dl-alpha tocopherol egg lecithin glycerol nitrogen sodium hydroxide sodium oleate water for injection - parenteral nutrition for adults and children aged 2 years and above when oral or enteral nutrition is impossible, insufficient or contraindicated

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - linezolid 2 mg/ml - solution for infusion - 2 mg/ml - active: linezolid 2 mg/ml excipient: citric acid glucose monohydrate hydrochloric acid sodium citrate sodium hydroxide water for injection - indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: - pneumonia - community acquired and nosocomial pneumonia - skin and soft tissue infections - enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - linezolid 2 mg/ml - solution for infusion - 2 mg/ml - active: linezolid 2 mg/ml excipient: citric acid glucose monohydrate hydrochloric acid sodium citrate sodium hydroxide water for injection - indicated for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: - pneumonia - community acquired and nosocomial pneumonia - skin and soft tissue infections - enterococcal infections. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected. consideration should be given to official guidance on the appropriate use of antibacterial agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 20%{relative};  ;   - solution for infusion - 20 % - active: soya oil 20%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - soya oil 30%{relative};  ;   - solution for infusion - 30 % - active: soya oil 30%{relative}     excipient: egg lecithin glycerol water for injection - part of the intravenous diet in all parenteral nutrition indications including: - preoperative and postoperative nutritional disturbances where an improved nitrogen balance is required; - nutritional disorders or disturbances of nitrogen balance due to inadequate or failing intestinal absorption caused by tumours in the gastrointestinal tract, acute or chronic intestinal diseases (peritonitis, ulcerative colitis, terminal ileitis); - burns, to reduce the frequently excessive nitrogen losses; - prolonged unconsciousness, eg following cranial trauma or poisoning in cases where enteral feeding is inappropriate or impossible; - impaired renal function where a concentrated source of energy may be indicated to reduce protein breakdown; - cachexia and - patients with essential fatty acid deficiency who cannot maintain or restore a normal essential fatty acid pattern by oral intake.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml - concentrate for injection - 1 mg/ml - active: granisetron hydrochloride 1.12 mg/ml equivalent to granisetron 1 mg/ml excipient: citric acid monohydrate hydrochloric acid sodium chloride sodium hydroxide water for injection - adults: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy. the prevention of nausea and vomiting induced by radiotherapy. the prevention and treatment of postoperative nausea and vomiting. children: granisetron is indicated for the prevention of nausea and vomiting induced by cytotoxic chemotherapy.